In line with this, recent investigations on clinically-derived tumor arrays have suggested that Ate1, an enzyme of the Arg/N-end rule pathway, may be down-regulated in some human cancers, such as kidney and colon, at the protein level. Here, ATE1 is linked to neoplasm.